Arrowhead Pharmaceuticals’ (ARWR) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWRFree Report) in a report issued on Thursday, Benzinga reports.

ARWR has been the topic of several other reports. Morgan Stanley decreased their price objective on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an equal weight rating on the stock in a report on Monday, May 13th. The Goldman Sachs Group started coverage on shares of Arrowhead Pharmaceuticals in a report on Wednesday, June 5th. They set a neutral rating and a $31.00 price objective on the stock. HC Wainwright reaffirmed a buy rating and set a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, June 11th. Finally, Chardan Capital reaffirmed a buy rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $47.89.

View Our Latest Stock Analysis on ARWR

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR opened at $25.50 on Thursday. The company’s fifty day moving average price is $24.08 and its 200 day moving average price is $28.32. Arrowhead Pharmaceuticals has a 1 year low of $20.67 and a 1 year high of $39.83. The company has a market capitalization of $3.17 billion, a PE ratio of -6.00 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWRGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. Arrowhead Pharmaceuticals’s revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.45 EPS. On average, equities analysts expect that Arrowhead Pharmaceuticals will post -3.05 EPS for the current year.

Insider Activity

In other news, Director Victoria Vakiener sold 1,799 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total value of $41,934.69. Following the completion of the sale, the director now directly owns 30,205 shares in the company, valued at $704,078.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 4.50% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of ARWR. Washington Trust Advisors Inc. acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $25,000. Neo Ivy Capital Management acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $41,000. Quest Partners LLC acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $45,000. Friedenthal Financial acquired a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $51,000. Finally, Headlands Technologies LLC increased its position in Arrowhead Pharmaceuticals by 7,696.8% during the first quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 2,386 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report)

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Further Reading

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.